tbuckley/cabot-search huggingface dataset:
Fears, Phobias, and Rituals. Panic, Anxiety, and Their Disorders.
Authors: Isaac Meyer Marks
Journal: Annals of Internal Medicine (1987)

NORMAL FEAR: Fear, defense and evolution Situations which evoke fear Fear behaviours: The four strategies Some fear adaptations ETIOLOGY: Development of fear Genetics of fear Physiology of fear Learning of fear CLINICAL SYNDROMES: Phobic and obsessive-compulsive phenomena: Classification, prevalence and relationship to other problems The agoraphobic syndrome (panic disorder with agoraphobia): Social and specific phobias Traumatic phobias, illness phobias, and children's phobias Obsessive-compulsive disorders (OCD) TREATMENT: Psychological treatment: Principles Psychological treatment: Clinical issues Physical treatment of phobic and obsessive-compulsive disorders.
Retrospective analysis of temozolomide (TMZ) plus BCNU wafers and TMZ alone in the primary treatment of glioblastoma multiforme
Authors: D. A. Bota, S. A. Taylor
Journal: Journal of Clinical Oncology (2006)

11519 Background: GBM is the most common and aggressive primary brain tumor with a median survival around 1 year. Two agents have shown promise and received recent approval by the Food and Drug Administration. A combination of these agents is frequently used with little data about the efficacy or toxicity. Methods: A retrospective review of patients (pts) treated between 1/2000 and 6/2004 was done to look at pts treated in such a manner. This review was approved by the IRB of the University of Kansas. Twenty-three pts were identified who had received TMZ or TMZ after surgery plus BCNU wafers (TMZ/B) at initial histologic diagnosis of their GBM. Median age was 53 years (26–71). Median KPS was 80 (50–100). 65% had subtotal resection and 35% gross total resection. The decision to place the wafers was at the discretion of the surgeon at the time of surgery. 10 pts received the wafers. All pts received standard radiation therapy. All pts received concurrent TMZ at 75mg/m2 during radiation therapy (XRT) and 150–200mg/m2 days 1–5 every 28 days depending upon myelosuppression seen during XRT. Results: Ten patients received TMZ/B and 13 received the TMZ alone. There were no differences between the groups in age or performance status (p&gt;0.3). At this time, 2/10 in the TMZ/B group and 1/13 in the TMZ are alive. Overall survival was the same in both groups. Median overall survival was 534 days for TMZ/B (95% confidence interval 369–700) and 596 days TMZ (95% CI 373–819). Toxicity was the same. Conclusions: This is a retrospective non randomized exploratory study which suggests there is no difference in survival or toxicity between the two treatments. Randomized studies will be needed to confirm this in larger pt numbers. At the present time, pts are frequently ineligible for experimental trials due to the frequent use of the BCNU wafers in the neurosurgical community. The results of TMZ may preclude the need for the wafers. [Table: see text]
Abstract 15293: Modulation of CETP by Dalcetrapib Increased CETP Induced Pre-β-HDL and Macrophage ABCA1 Cholesterol Efflux of Human Plasma in vitro
Authors: Cyrille Maugeais, Anne Perez, Elisabeth von der Mark, Eric J Niesor
Journal: Circulation (2011)

Introduction: Dalcetrapib selectively modulates cholesteryl ester transfer protein (CETP) activity in vitro. Transfer of cholesteryl esters (CE) between HDL and ApoB-containing lipoproteins is inhi...
Discovery of substituted isoquinolinediones as potent and selective inhibitors of cyclin-dependent kinase 4: 2. Benzylenamine series
Authors: Hwei-Ru Tsou, Xiaoxiang Liu, Gary Birnberg, Josh Kaplan, Mercy Otteng, Tritin Tran, Kristina Kutterer, Zhilian Tang, Ron Suayan, Arie Zask, Semiramis Ayral-Kaloustian, Malini Ravi, Mary Grillo, John McGinnis, Sridhar Rabindran
Journal: Cancer Research (2007)

4370   Inhibition of cyclin-dependent kinase 4 (CDK4) is predicted to provide an effective therapeutic treatment for cancer. Design and discovery of small molecule inhibitors that are selective for CDK4 have been actively pursued in many laboratories. However, achieving high levels of selectivity for CDK4, versus other CDKs and ATP-dependent kinases, presents a significant challenge. We demonstrate that isoquinolinedione is an attractive scaffold for selective CDK4 inhibitors. Adding a substituted benzylenamine moiety to the scaffold yielded highly potent and selective inhibitors of CDK4. Replacing the phenyl ring of the benzylenamine moiety with a pyridyl ring also generated potent and selective CDK4 inhibitors. Molecular modeling will be presented to demonstrate the key interactions with the CDK4 enzyme. We will also present the synthesis and SAR for the series.
Medicare Approves Coverage for Lung Cancer Screening
Authors: Vivek Verma, Sushil Beriwal
Journal: JAMA Oncology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A clinical, radiological and microbiological profile of lung abscess
Authors: Maria Malik, Shaista Ghazal, Ashok Kumara, Nadeem Rizvi
Journal: European Respiratory Journal (2012)

Introduction   Lung abscesses continue to be a frequent presentation for physicians in Pakistan.With little local data available on the clinical correlations of the disease,there is a pressing need to describe the various factors associated with the condition.   Objectives   To evaluate the clinical,radiological and microbiological profile of lung abscess.   Methods   A retrospective case study was done through studying hospital records of 41 patients admitted with lung abscess at a tertiary care hospital in Karachi,Pakistan.Demographical data,clinical symptoms,risk factor assessment,radiological findings and culture reports were studied to outline a relevant profile.   Results   Over half the cases comprised of adult,male patients.Clinically,90.2% presented with productive cough,followed by 82.9% with fever, and 58.5% with haemoptysis.A significant association of 65.9%was found with smoking.Among other risk factors, poor oral hygiene was found in 56.1% of the cases, diabetes mellitus in 43.9%, pneumonia in 22%, and malignancy was diagnosed in 4.9%. Radiographically, 56.1% showed bilateral and 51.2% had right lower lung zone involvement. Sputum Gram staining revealed Gram negative rods and Gram positive cocci in 36.6% of the cases. AFB smear was positive in 22%. Sputum cultures showed Pseudomonas aeruginosa was present in 29.3%. No growth on blood cultures was seen in 86.6% and only 9.8% exhibited growth of E. coli.   Conclusion   Lung abscess was found to be more common in adult men,and was significantly related to smoking.The other common risk factor was found to be poor oral hygiene,while the right lower lung zone was the main site of abscess formation.Pseudomonas aeruginosa was the major pathogen implicated on sputum cultures.
Abstract 1815: Resveratrol, an Activator of Protein Deacetylase SIRT1, Suppresses Oxidative Stress-Induced Cell Death by Upregulating MnSOD Expression through Transactivation of FOXO3a
Authors: Atsushi Kuno, Masaya Tanno, Tetsuji Miura, Yoshiyuki Horio, Kazuaki Shimamoto
Journal: Circulation (2008)

[Purpose] SIRT1, a class III protein deacetylase, contributes to cell survival under oxidative stress. Although MnSOD plays a crucial role in prevention of oxidant-induced cell death, its expression is reduced in failing hearts, and there are few currently available interventions to upregulate MnSOD in the myocardium. Here, we examined whether and how resveratrol (RSV), an activator of SIRT1, upregulates MnSOD and reduces oxidative stress-induced cell death.  [Methods and Results] First, the effect of RSV on activity of SIRT1 was examined in C2C12 myoblast cells. RSV deacetylated histone H3 Lys 9 and histone H4 Lys 16, both of which are targets of SIRT1, in the presence of a class I and II HDAC inhibitor, trichostatin A. The deacetylation by RSV was completely inhibited by SIRT1-siRNA, confirming that SIRT1 is essential for deacetylation by RSV. Next, we examined the effect of RSV on oxidative stress-induced apoptosis detected by nuclear condensation with Hoechst 33342 staining. Exposure of C2C12 cells to antimycin A (AA), an oxidant stressor, enhanced the dichlorofluorescein (DCF) signal and induced apoptosis. RSV significantly decreased DCF signal and suppressed the apoptosis compared with those in the case of a vehicle (24.9Â ±1.7% vs. 33.3Â ±1.7%, p=0.04). Although inhibition of p53 is known to play a role in cytoprotection by SIRT1, this mechanism is unlikely to operate in our model because AA failed to upregulate p53 mRNA. In contrast, MnSOD protein was increased by 31% after RSV treatment in the presence of AA, and siRNA-mediated knockdown of MnSOD abolished RSV-induced protection, demonstrating that upregulation of MnSOD is indispensable in the protection. Finally, we examined the role of forkhead box O transcription factors (FOXO), a target of SIRT1, in the MnSOD induction under oxidative stress. Chromatin immunoprecipitation assay revealed that the amount of FOXO3a, but not that of FOXO1 or FOXO4, bound in the MnSOD promoter region was significantly increased by AA treatment.  [Conclusion] RSV promotes MnSOD expression under oxidative stress via FOXO3a transactivation in a SIRT1-dependent manner, which affords protection against oxidant-induced cell death. RSV may be applicable for restoration of MnSOD level in failing hearts.
Incidence, Predictive Factors, and Prognostic Value of New-Onset Atrial Fibrillation After Transcatheter AorticValve Implantation
Authors: Sacha P. Salzberg, Maximillan Y. Emmert, Roberto Corti, Volkmar Falk, Jürg Grüenenfelder
Journal: Journal of the American College of Cardiology (2012)
Allergen IgE‐isotype‐specific suppression by maternally derived monoclonal anti‐IgG‐idiotype
Authors: R. I. Tanasa, A. Trad, H. Lange, J. Grötzinger, H. Lemke
Journal: Allergy (2009)

The dramatic increase of IgE-mediated allergic diseases in western countries demonstrates the urgent need for new therapeutic or prophylactic approaches. In mice, a prophylactic long-lasting allergen-specific suppression of IgE responsiveness is induced by maternal IgG antibodies to allergens like ovalbumin, phospholipase A(2) (bvPLA(2)) or ovomucoid. As neonatal application or maternally derived pathogen-reactive antibodies (idiotypes) as well as corresponding anti-idiotypes can induce anti-microbial protection, we probed the transgenerational IgE-suppressive mechanism with a syngeneic monoclonal anti-idiotypic antibody.The monoclonal bee-venom-phospholipase A(2) (bvPLA(2))-reactive IgG antibody MS613 (idiotype) or the corresponding syngeneic anti-idiotype II/2-19 were injected during the first 2 days postpartum to the dams. Immunization of offspring with minute doses of IgE-inducing bvPLA(2) was started at an adult age of 3(1/2) months.The postnatal transfer of the anti-bvPLA(2) idiotype MS613 or the corresponding anti-idiotype II/2-19 induced long-lasting allergen-specific IgE suppression in a dose-dependent manner, while the IgG response to the allergen developed normally. Quantitatively, the anti-idiotype was more effective than idiotype. Molecular modeling of the idiotype-anti-idiotype complex and its comparison with the bvPLA(2) structure revealed that the anti-idiotype does not mimic bvPLA(2) epitopes and thus can not be regarded as an internal image antibody and, consequently, does not function as a surrogate antigen.Idiotypic network reactivity is at least one major factor for induction of transgenerational IgE suppression by maternal IgG antibodies. If applicable to humans, these data suggest the possibility of a prophylactic and possibly therapeutic treatment of IgE-mediated allergic diseases with anti-idiotypic antibodies.
167. Partial Correction of the Hemophilic Phenotype in Mice Implanted with Encapsulated Human Primary Myoblasts Secreting FIX
Authors: Jianping Wen, Frederick A. Ofosu, Gonzalo Hortelano
Journal: Molecular Therapy (2004)

Top of pageAbstract
Hemophilia B is a bleeding disease caused by a defective factor IX (FIX). Current treatment includes infusion of concentrated FIX derived from plasma or recombinant FIX. Alternative treatments would be highly desirable. We propose a gene therapy strategy based on the use of recombinant cell enclosed in the implantable alginate microcapsules. Previously, we have reported a transient delivery of hFIX with implantation of encapsulated C2C12 myoblasts and sustained delivery of hFIX with implantation of encapsulated mouse primary myoblasts in immune competent mice. As the purpose of the study of the gene therapy is for treatment of human patients, in this study we report on the feasibility of encapsulated genetically engineered human primary myoblasts to correct the bleeding disorder of FIX deficient mice. Human primary myoblasts were transfected with plasmid pKL4M-hFIX containing hFIX cDNA driven by the ubiquitous β-actin promoter. Transfected cells were selected with G418 and clones secreting high levels of hFIX selected by ELISA. Clone pKL4M-hFIX-C12, secreting 900 ng hFIX/106/24hr in vitro, was used in this study. The recombinant human primary myoblasts were enclosed in 1.7% alginate-PLL microcapsules with a diameter of 500–600 μm. Encapsulated cells were subsequently implanted intraperitoneally into immune competent C57BL/6 (6–8 weeks of age) hemophilic mice. Each mouse received 20 × 106 cells. Circulating level of hFIX in treated mice as detected by ELISA was on average 68 ng/ml, with a peak of ~120 ng/ml on day one after implantation. The level of circulating hFIX was reduced by day 7 and could not be detected after day 14. A plausible cause for the transient delivery of hFIX might be the anti-hFIX antibodies that were detected in the treated mice following the xenotransplant. At the same time, APTT values in the treated mice were gradually reduced on average from 88.9 sec before treatment to 74.6 sec after treatment. Mice were also subjected to a tail transection test to assess the protection of treated mice against severe trauma. Importantly, tail-cut bleeding time decreased from more than 15 min before treatment to 5 min post-treatment. Control non-hemophilic mice stop bleeding in approximately 3 min. Interestingly, in selected treated hemophilic mice, bleeding was completely corrected (i.e. tail-cut bleeding time went back to normal). Taken together, these results indicate that the hFIX secreted from the encapsulated cells in mouse plasma and tissue has strong biological activity. Therefore, our findings would support the feasibility of human encapsulated myoblasts as a gene therapy strategy for hemophilia B.
Inhalation of Racemic Epinephrine in Children with Asthma
Authors: B. Kjellmas, H. Tollig, G. Wettrell
Journal: Allergy (1980)

In this study the effects of nebulized racemic epinephrine (Micronephrine) were investigated in children with asthma. The drug was inhaled by a compressor nebulizator with a plastic mask. In the first part of the study it is shown that nebulized Micronephrine has a dose‐dependent bronchodilatory effect. In the second part the effect is compared with that of nebulized salbutamol 10 children (7‐16 years of age) with bronchial asthma. The highest dose used in the dose‐response trials (=0.9 mg Micronephrine/kg body‐weight) was compared with 0.15 mg salbutamol/kg body‐weight, which is the dose commonly used in Sweden There was no significant difference between the drugs as regards increase of forced expiratory volume in 1 sec or duration of the increase. The was a small but significant increase in systolic blood pressure, measured 5 min after the inhalation of Micronephrine but no significant change in diastolic pressure of heart rate. Four children complained of temporary sore throat after the inhalation.
Abstract 18006: The Relationship Between Residual ST-segment Deviation and Biomarkers in Patients with STEMI Undergoing Primary PCI: A Sub-analysis of the On-TIME 2 Trial
Authors: Arthur van Zoelen, Evangelos Giannitsis, Jurrien ten Berg, Jan Hoorntje, Harry Suryapranata, Christian Hamm, Arnoud W van 't Hof
Journal: Circulation (2010)

Background:  Pre-hospital initiation of High-bolus Dose Tirofiban (HDT) improves ST-segment resolution before and after pPCI which is associated with improved clinical outcome at 30 day follow-up. We investigated the relation between residual ST-segment deviation (STres) and several known biomarkers of myocardial necrosis and heart failure   Methods:  In On-TIME 2, 984 patients presenting with STEMI were randomized in the ambulance to either high-bolus dose tirofiban or placebo in addition to aspirin (500 mg), heparin (5000 IU), and clopidogrel (600 mg). The primary end point was the extent of STres 1 hour after pPCI with a cut-off at 3 mm. Blood samples were taken at the time of the pPCI (baseline), 18–24 and 72–96 hours thereafter. Mean cardiac troponin T, NT-proBNP (two assays) and CK-max levels were analyzed in relation to high STres(> 3mm) 1 hour after pPCI.   Results:  Early initiation of HDT significantly reduced the percentage of patients with high STres (HDT 172/451 (38.1%), placebo: 205/455 (45.1%), p=0.035). Patients high STres had significantly higher levels of cardiac troponin T (0.58 ± SD 1.59 vs. 0.20 ± SD 0.80; p   Conclusions:  Residual ST-segment deviation of more than 3 mm one hour after pPCI is associated with significantly higher levels of biomarkers indicative of myocardial necrosis or heart failure both before and after pPCI. This simple electrocardiographic marker for which only one 12 lead ECG is required may help in risk stratifying STEMI patients early after pPCI
Law Commission's report makes no provision for dissenting doctors
Authors: A P Cole
Journal: BMJ (1995)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Law Commission's report makes no provision for dissenting doctors Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday
Authors: A J Rothschild
Journal: American Journal of Psychiatry (1995)

The purpose of this study was to evaluate whether weekend drug holidays would improve sexual functioning in recovered depressed patients with selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction.Thirty outpatients who reported worsening of sexual functioning during SSRI treatment were instructed to discontinue their SSRIs after the Thursday morning dose and to restart the SSRIs (at their previous dosage) on Sunday at 12:00 noon for four weekends.Significant improvement in sexual functioning was reported by the patients taking sertraline and paroxetine but not by those taking fluoxetine. There were no statistically significant increases in mean Hamilton depression scores after discontinuation of the SSRIs; two patients had increases in scores from the 4-8 range to the 10-14 range.For some patients taking sertraline and paroxetine who experience sexual dysfunction side effects, brief drug holidays may allow for significant improvement in sexual functioning without a significant return of depressive symptoms.
Controlled dual delivery of fibroblast growth factor-2 and Interleukin-10 by heparin-based coacervate synergistically enhances ischemic heart repair
Authors: William C.W. Chen, Brandon G. Lee, Dae Woo Park, Kyobum Kim, Hunghao Chu, Kang Kim, Johnny Huard, Yadong Wang
Journal: Biomaterials (2015)
Abstract 9729: Should HF Preserved-Ejection Fraction Patients Participate in a HF Program?
Authors: Linda Kelly, Gregg Steahr, Brenda Hott
Journal: Circulation (2014)

Introduction:  Optimal treatment regimens for individuals with Heart Failure preserved Ejection Fraction (HFpEF) have yet to be defined and these patients comprise nearly half the heart failure (HF) population. We present outcomes of this patient population from our first year in a heart failure program (HFP).   Hypothesis:  HFpEF patients will benefit as much as heart failure reduced ejection fraction (HFrEF) patients from a HFP.   Methods:  Retrospective review of 142 HFP patients (HFpEF n=56, HFrEF n=86). Baseline, 3 and 6 month assessments of NYHA class, six minute walk, and Minnesota Living with Heart Failure Questionnaire (MLWHF) were completed. Three month hospital admissions before and after HFP enrollment were reviewed.  The HFP provides an inpatient consult service for acutely decompensated HF patients and weekly interdisciplinary rounds. Transition of care with telemonitoring for 30 days post discharge assessing med reconciliation, weight, BP, signs of worsening HF and treatment as needed . The outpatient HF Clinic optimizes guideline directed medical therapy (GDMT), provides self-care education with HFSA modules, exercise prescriptions, dietician consults, and intravenous diuretics if needed.   Results:  HFpEF comprised 39% of all patients in the HFP. HFpEF group had more females-(HFpEF-52%, HFrEF-35%). HFrEF patients had more CAD. No differences in the comorbidities of AF, HTN, DM, CKD, COPD, anemia or NA level were seen. Similar GDMT utilization was observed in both groups. HFrEF and HFpEF improved NYHA Class, 6MW, and QOL over the first six months. Compared to 3 months before HFP enrollment, all-cause admissions 3 months after HFP were reduced by 81% in the HFpEF vs 60% in the HFrEF group (p=0.0236).   Conclusions:  Both HFpEF and HFrEF benefit from enrollment in a HFP. HFpEF saw a greater reduction in all-cause three month readmissions after enrolling in the HFP. The QOL and functional improvements reach significance in both groups at six months.
Abstract 12173: TEVAR versus Open Descending Thoracic Aortic Repair for the Treatment of Thoracic Aortic Aneurysms: An Analysis of the Medicare Database
Authors: Justin M Schaffer, Bharathi Lingala, Michael P Fischbein, Y J Woo, R S Mitchell, D C Miller, Michael D Dake
Journal: Circulation (2014)

Introduction: Treatment of aneurysms of the descending thoracic aortic (TAA) was revolutionized with thoracic endovascular aortic repair (TEVAR). Whether TEVAR or open descending thoracic aortic repair (ODTAR) is the most appropriate intervention for TAAs remains controversial. Hypothesis: We hypothesized that TEVAR would be associated with improved early survival, but have an increased late hazard phase of death compared with ODTAR. Methods: We reviewed Medicare patients with a TAA undergoing ODTAR (n= 1037) and TEVAR (n=2010) but no concomitant operation from 1999-2010. CPT codes were used to identify procedural characteristics. Survival distributions were estimated with the Kaplan-Meier method; the log-rank test was used to compare differences between distributions. Analyses were repeated with using inverse probability of treatment weighting (IPTW) analysis to account for differences between groups. A flexible parametric analysis was used to model the time varying hazard of TEVAR compared with ODTAR. R...